Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 26, 2016

View Archived Issues

Evotec and Inserm establish oncology research collaboration

Zhejiang DTRM Biopharma initiates phase I trial of DTRMWXHS-12

Charles River enters partnership agreement with Tri-I TDI

FDA grants orphan drug designation to BIIB-067 for the treatment of ALS

Grant supports collaborative research into uveal melanoma

UC Riverside to evaluate ecopipam for the treatment of stuttering

Allele receives NIH Grant to develop a new antibody therapy for Alzheimer's disease

Asit Biotech to start a phase IIa trial of Hdm-Asit

Immunotoxin D2C7-(scdsFv)-PE38 KDEL receives FDA orphan status for glioma

Aurigene Discovery Technologies patents PD-1 signaling inhibitors

Merck & Co. discloses IRAK-4 inhibitors

Peloton Therapeutics describes HIF-2alpha inhibitors

Janssen Biotech submits BLA to the FDA for sirukumab

Bristol-Myers Squibb develops ROCK2 inhibitors

FDA approves adalimumab biosimilar Amjevita

Fate Therapeutics' ProTmune receives orphan drug designation

FDA accepts for priority review dupilumab BLA for atopic dermatitis

FDA grants expanded use approvals for Novartis' canakinumab

Ligand licenses programs to Seelos Therapeutics

FDA approves Rexulti labeling update for maintenance treatment of schizophrenia

MELK inhibition overcomes drug resistance in myeloma cell lines

Neuregulin 1 is a potential novel therapeutic target for the treatment of Alzheimer's disease

Enrollment open in Chugai's phase I trial of ERY-974 for advanced solid tumors

Peptide-mediated oligonucleotide therapy to enter clinical development for spinal muscular atrophy

FDA grants orphan drug designation to modafinil/flecainide fixed dose combination

SK Life Science initiates phase III trial of YKP-3089 for partial onset seizures

Therapy with HDAC6 inhibitor rocilinostat shows promising activity in multiple myeloma trial

Dysferin gene therapy given US orphan status for limb girdle muscular dystrophy type 2B

RO-4993850 attenuates social deficits in schizophrenia model

Reduced soluble CD93 levels linked to type 2 diabetes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...